CDRD, EATRIS, TIA, and NCATS join forces to share knowledge and insight
The Centre for Drug Research and Development (CDRD), Canada’s national drug development and commercialization centre has joined forces with four major translational health research organisations to launch a global collaboration in the field of translational research in medicine.
Therapeutic Innovation Australia (TIA), EATRIS ERIC, the European Infrastructure for Translational Medicine, and the US-based National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS) will be working in partnership with CDRD to identify and seek solutions to major bottlenecks in this key area of medical research. Translational research is the multi-disciplinary process of developing novel discoveries made in the laboratory and clinic, into new diagnostic and therapeutic interventions that improve the health of individuals.
Led by experts from each of the participating organisations, the initiative aims to drive research forward through a number of expert-led meetings. By identifying globally relevant issues, such as those around high development failure rates and reproducibility of data, the initiative will support in developing a coherent approach to improving the output of novel drugs and diagnostics with high benefit for patients and the public.
Karimah Es Sabar, President and CEO of CDRD commented, “By focusing on the systemic issues in the translational process, and coming together to leverage the collective strengths, knowledge and resources of these innovative organizations, we can bring new solutions and standards to improve the output of new patient interventions around the world. Such partnership and collaboration amongst world-leading organizations is critical to addressing this area of great global significance.”
For further information about CDRD, EATRIS, TIA, and NCATS, please visit:
For further information please contact:
About The Centre for Drug Research and Development (CDRD)
CDRD is Canada’s fully-integrated national drug development and commercialisation centre, providing expertise and infrastructure to enable researchers from leading health research institutions to advance promising early-stage drug candidates. Its mandate is to de-risk discoveries stemming from publicly-funded health research and transform them into viable investment opportunities for the private sector — thus successfully bridging the commercialization gap between academia and industry, and translating research discoveries into new therapies for patients. Canada’s Networks of Centres of Excellence Program has recognized CDRD as a Centre of Excellence for Commercialization and Research (CECR). www.cdrd.ca
About EATRIS ERICEATRIS ERIC
The European Infrastructure for Translational Medicine is comprised of leading academic groups and institutions in eight countries, which provide access to innovative translational research infrastructure and expertise. They leverage their state-of-the-art facilities and knowledge to reduce risks within translational research across Europe, while increasing productivity. Participating institutes are selected on the basis of the available infrastructure, expertise and quality standards which comply with current European pharmaceutical regulations, laws and guidelines. As a European Research Infrastructure Consortium (ERIC) hosted in Amsterdam, The Netherlands, EATRIS ‘Coordination & Support’ provides one-stop access to over 70 research centres of excellence across Europe. www.eatris.eu
About the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS)
NCATS is a distinctly different entity in the research ecosystem. Rather than targeting a particular disease or fundamental science, NCATS focuses on what is common across diseases and the translational process. This NIH Center emphasizes innovation and deliverables, relying on the power of data and new technologies to develop, demonstrate and disseminate advances in translational science that bring about tangible improvements in human health. For more information, visit www.ncats.nih.gov.
Therapeutic Innovation Australia (TIA)
TIA is a not-for-profit charitable organization which aims to improve the efficiency and effectiveness of translational research.
TIA enables researchers to access over $500M worth of research infrastructure, it operates six national advisory committees and it has recently launched the Australian Therapeutic Pipeline; an initiative which will lift Australia’s capacity to translate health discoveries into clinical applications.
TIA is funded by the Australian Government as part of the National Collaborative Research Infrastructure Strategy (NCRIS).
To learn more visit our website at www.therapeuticinnovation.com.au